Pfizer has entered into a global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The agreement covers 12 early-stage oncology programs, including antibody-drug conjugates and multispecific antibodies. Innovent will receive $650 million upfront, with the remaining value tied to development, regulatory, and commercial milestones. Collaboration Overview 12 early-stage oncology programs 8 Innovent-originated candidates […]
Eli Lilly and Company has announced acquisitions of three vaccine developers – Curevo, LimmaTech Biologics, and Vaccine Company – in deals valued at up to approximately $3.8 billion combined. The move signals Lilly’s renewed focus on infectious disease prevention and vaccine innovation. Acquisition Overview Curevo | up to $1.5B Developing a next-generation shingles vaccine candidate, […]
Bristol Myers Squibb and Hengrui Pharma have announced a global strategic collaboration and licensing agreement worth up to $15.2 billion. The collaboration covers 13 early-stage programmes across oncology, hematology, and immunology. Rather than a single asset licensing deal, this partnership combines multiple candidates and newly discovered programmes within a broader co-development framework. Partnership highlights 13 […]
UCB has announced an agreement to acquire U.S.-based Neurona Therapeutics for up to $1.15 billion, extending its long-established epilepsy franchise into regenerative medicine and advanced therapies. Neurona’s lead asset, NRTX-1001, is a neuronal cell therapy being developed in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy. Designed as a single-dose approach aimed at restoring […]
Eli Lilly and Company has announced an agreement to acquire Houston-based biotech CrossBridge Bio in a deal valued at up to $300 million, adding an early-stage dual-payload ADC platform to its oncology pipeline. Founded in 2023, CrossBridge is a preclinical company built around technology originating from UTHealth Houston. Key points Total deal value of up […]
Gilead Sciences has announced an agreement to acquire Germany-based clinical-stage biotech Tubulis in a deal valued at up to $5 billion, expanding its oncology pipeline through next-generation antibody-drug conjugate, or ADC, technology. The acquisition adds Tubulis’ lead programme TUB-040, along with its proprietary Tubutecan linker-payload technology and broader ADC platform. The transaction also builds on […]
Last week, Greenstaff Life Sciences attended BIOCHINA2026 in Suzhou, China. Hiroshi Yamaguchi, Head of Greenstaff Life Sciences, and Summer Wang, Director of Greenstaff Medical China, attended the conference and engaged in discussions and exchanges across the life sciences community. Across the event, strong discussions took place around innovation, collaboration, and the future of biotech in […]
In March 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted conditional marketing authorization to two regenerative medicine products derived from induced pluripotent stem cells (iPSCs). The decision represents a significant milestone for the regenerative medicine sector, as these therapies could become the first iPSC-based treatments to receive regulatory approval globally. Since induced pluripotent […]
Gilead Sciences has entered into a definitive agreement to acquire Arcellx for approximately $7.8 billion, securing full ownership of its next-generation CAR-T program. Transaction & Development Overview Total deal value: approximately $7.8B (upfront plus contingent value rights) Lead asset: anitocabtagene autoleucel (anito-cel) BCMA-directed CAR-T therapy Target indication: relapsed/refractory multiple myeloma Clinical studies indicate deep and […]
After a prolonged period of limited public market activity, the US biotech sector saw a notable shift last week. Several biotech companies completed IPOs or filed to go public, collectively raising more than $1 billion. Leading industry media have described this as a selective reopening of the IPO market, rather than a broad-based recovery. Recent […]